Preparation and in vitro evaluation of B-lipiodol as a boron delivery agent for neutron capture therapy of hepatoma.
BACKGROUND
We prepared boron containing lipiodol (B-lipiodol), elucidated the retention of B-lipiodol in hepatoma cells and evaluated the in vitro cellular toxicity of B-lipiodol for neutron capture therapy.


METHODS
Human hepatoma HepG2 cells were used to examine the uptake and retention of B-lipiodol. Light microscopes were used to examine the interaction and retention of B-lipiodol globules in individual hepatoma cells. Boron and lipiodol concentrations were determined by inductively coupled plasma-atomic emission spectroscopy and neutron activation analysis, respectively.


RESULTS
The boron concentration in B-lipiodol drug could reach 2500 ppm. B-lipiodol could be stably retained in serum and culture medium. HepG2 cells appeared proficiently at internalization and persistent retention of B-lipiodol. The boron concentration reached 3.5 micrograms/10(6) cells without approaching saturation at 48 h treatment.


CONCLUSIONS
Hepatoma cells could actively uptake B-lipiodol and a sufficient amount of boron was retained inside the HepG2 cells which could be used for neutron capture therapy.
Chou
F I
FI
Nuclear Science and Technology Development Center, National Tsing Hua University, Taiwan, Republic of China. fichou@nstdc.nthu.edu.tw
Lui
W Y
WY
Wei
Y Y
YY
Chung
R J
RJ
Kai
J J
JJ
Chi
C W
CW
D000818:Animals; D001895:Boron / Q000008:administration & dosage* / Q000627:therapeutic use / Q000633:toxicity; D016754:Boron Neutron Capture Therapy; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000532:radiotherapy*; D004337:Drug Carriers; D004705:Endocytosis; D005240:Feasibility Studies; D006801:Humans; D007459:Iodized Oil / Q000008:administration & dosage* / Q000633:toxicity; D007554:Isotopes; D008113:Liver Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D014407:Tumor Cells, Cultured
D004337:Drug Carriers; D007554:Isotopes; D007459:Iodized Oil; D001895:Boron